From our recent publication of the STRONG-HF study (37), we have learned that rapid up-titration of heart failure therapies under close follow-up (including clinical examination and NT-proBNP monitoring) is safe, reduces heart failure readmissions and all-cause mortality, and improves patients’ health-related quality of life. This evidence concerns the gene NPPB and hydrops fetalis.